Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience

Aim: To evaluate the clinical course of idiopathic inflammatory myopathy (IIM) patients in COVID-19 pandemic, and to assess the COVID-19 outcomes in infected IIM patients. Materials & methods: In this study, 39 patients were evaluated retrospectively. Myositis disease activity, myositis damage i...

Descripción completa

Detalles Bibliográficos
Autores principales: Apaydin, Hakan, Erden, Abdulsamet, Güven, Serdar C, Armağan, Berkan, Karakaş, Özlem, Özdemir, Bahar, Polat, Bünyamin, Eksin, Mehmet Akif, Omma, Ahmet, Kucuksahin, Orhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203034/
https://www.ncbi.nlm.nih.gov/pubmed/35747325
http://dx.doi.org/10.2217/fvl-2021-0146
Descripción
Sumario:Aim: To evaluate the clinical course of idiopathic inflammatory myopathy (IIM) patients in COVID-19 pandemic, and to assess the COVID-19 outcomes in infected IIM patients. Materials & methods: In this study, 39 patients were evaluated retrospectively. Myositis disease activity, myositis damage index, depression, fatigue, active medical treatment, drug compliance and SARS-CoV-2 PCR test results in COVID-19 pandemic were collected. Results: Fourteen of these patients (35%) were detected to have a positive SARS-CoV-2 PCR test. The demographic and clinical characteristics, active medical treatment, disease activity, depression and fatigue of the patients who had undergone or not SARS-CoV-2 were similar. Conclusion: Our results have shown that although prevalence of COVID-19 seems to be increased in IIM patients under immunosuppressive treatment, hospitalization rates were lower and no intensive care unit admissions or deaths were observed.

Ejemplares similares